Genetic And Transcript Changesin Cereblon In Imid-Treated Myeloma Patients

Sarah Gooding,Naser Ansari-Pour,Fadi Towfic,Maria Ortiz,Dan Rozelle,Victoria Zadorozhny,Michael Amatangelo,Erin Flynt,Kao-Tai Tsai,Paola Neri,Nizar Bahlis,Paresh Vyas,Anjan Thakurta

BLOOD（2019）

引用 0|浏览7

暂无评分

摘要

Myeloma survival has been significantly improved by novel therapies over the past two decades. Immunomodulatory agents (IMiDs, Lenalidomide (LEN) and Pomalidomide (POM)) are a backbone of current treatment strategies. But myeloma (MM) remains incurable, because patients ultimately relapse.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要